Kornimate/medical-research-clean huggingface dataset:
effects of silver spike point therapy on pelvic girdle pain pain

Conditions: Pelvic Girdle Pain

Summary: the aim of this study is to determine the effects of silver spike point therapy (sspt) therapy on pelvic girdle pain and functional activities in pregnancy.the finding of this study will help to establish the role of sspt therapy to relieve pelvic girdle pain in pregnant females along with exercises. ssp for pelvic girdle pain management can prove to be a useful method. the findings of this study can play a role to establish more rigorous treatment plans for pelvic girdle pain in the pregnant population in the future.

this study will be a randomized clinical trial that will investigate the effectiveness of silver spike point therapy and manual therapy in subjects with pregnancy-related pelvic girdle pain. subjects with pregnancy-related pelvic girdle pain meeting the predetermined inclusion \& exclusion criteria will be divided into two groups using the lottery method. pre-assessment will be done using nprs and pgpq as subjective measurements and psfs as objective measurements. subjects in one group will be treated with silver spike point therapy and manual therapy, the other will be treated with manual therapy only. each subject will receive 10 treatment sessions, with 05 treatment sessions per week. post-treatment reading for nprs, pgpq, and psfs will be recorded after the end of the 10th treatment session. recorded values will be analyzed for any significant difference between pre and post-treatment values spss 21.

Eligibility criteria:
inclusion criteria: * female aged between 20 to 40 years of age * healthy pregnancy * 14 to 38 weeks gestation * expecting a singleton fetus * 2 out of 3 tests positive for pgp according to european guidelines for * pelvic girdle pain"(posterior pelvic pain provocation (p4), patrick's faber, modified trendelenburg's test) exclusion criteria: * high-risk pregnancy, caudaequina syndrome, trauma, or spinal surgical history. * inflammatory, infective, metabolic, neoplastic, or degenerative conditions. * sensory symptoms associated with disc herniation or compressive spinal lesion. * any contraindication to exercise.

Keywords: pelvic girdle pain
repetitive transcranial magnetic stimulation (rtms) for tinnitus

Conditions: Tinnitus

Summary: tinnitus is a phantom auditory perception of meaningless sound, meaning that there is registration of sound in the absence of an external or internal acoustic stimulus. it is a common problem (prevalence 7-19%) which may interfere with the ability to lead a normal life. unfortunately, it is a very difficult symptom to treat because there are hardly any therapeutic options for the cause of tinnitus. most therapies focus on alleviating the condition rather than treating the cause. tinnitus is thought to be generated in the brain, as a result of functional reorganization of auditory neural pathways and tonotopic maps in the central auditory system, following damage to the peripheral auditory system. repetitive transcranial magnetic stimulation (rtms) is a therapy, based on this concept of reorganization in the auditory cortex. it uses a pulsed magnetic field to disrupt the neural circuit and to thereby (temporarily) excite or inhibit certain brain areas, leading to the suppression of tinnitus.


Eligibility criteria:
inclusion criteria: * chronic, non fluctuating, tinnitus, demonstrated by means of the diagnostic protocol tinnitus umcu, of at least two months duration. * age ≥18 years * dutch speaking exclusion criteria: * treatable cause of the tinnitus * use of anticonvulsant medication or other psychotherapeutic drugs * history of epilepsy or family members with epilepsy * presence of active migraine * presence of psychiatric, severe internal or heart diseases or other neurologic diseases besides epilepsy * metal objects in and around body that can not be removed * pregnancy (will be tested on the first day of rtms using a urine pregnancy test) * alcohol or drug abuse * prior treatment with tms

Keywords: tinnitus transcranial magnetic stimulation
accelerated neuromodulation to alleviate cognitive deficits due to cancer therapy

Conditions: Cancer

Summary: this project is aimed at the discovery of neuro-modulation techniques that may alleviate chemotherapy induced cognitive deficits (cicd), especially in executive (higher-order) cognitive function (ef).

the specific aim for this study is to use magnetic resonance spectroscopy (mrs), self-report, and neuropsychological testing to identify changes in brain metabolite concentrations/ratios and changes in ef deficits associated with chemotherapy, before and after accelerated theta-burst transcranial stimulation (itbs). the secondary aim is to assess for any association of changes in executive function with brain metabolite concentrations.

Eligibility criteria:
inclusion criteria: * women or men with a history of non-metastatic cancer who have completed definitive curative cancer therapy * received cytotoxic chemotherapy as a part of their therapy for cancer and at least one month has passed since the final cytotoxic chemotherapy treatment * ≥ 18 years of age at time of cancer diagnosis and receipt of chemotherapy * patients must report subjective symptoms of "chemo-brain" (memory loss, difficulty with concentration, word-finding difficulties) with a fact-cog perceived cognitive impairment score \< 60 * ability to sign informed consent and comply with study procedures exclusion criteria: * patients with a recurrence of cancer or those with current metastatic disease * patients with a history or current diagnosis of brain metastasis * patients with a history or current diagnosis of a primary brain tumor * patients with a history of brain surgery or brain radiation * patients receiving maintenance systemic therapy for cancer, other than endocrine therapy * patients who cannot produce or request adequate medical record documentation to ensure they meet inclusion and exclusion criteria * women who are currently pregnant * history of childhood cancer or receipt of chemotherapy in childhood (\<age 18). developmental insult to the pfc, can be associated with long-term, durable and sometime debilitating cognitive deficits. hence, we avoid any cognitive confounds that maybe related to this issue. * patients with a weight over 250 lbs., as these patients would not fit in the mri scanner used in the protocol * patients who require benzodiazepines for mri due to claustrophobic anxiety * patients with chest wall tissue expanders or other retained 7 tesla mri-incompatible metal. any other specific contraindication to tms or mri not already listed above, including: * (a) any implanted device in the head, neck or upper body (e.g. cochlear implant, cranial or other electrodes, pacemaker or defibrillator, medication pump, stent, aneurysm clip, etc.) * (b) personal history of seizures or epilepsy, personal history of multiple concussions or unexplained loss of consciousness. this will be determined by physician judgement * history of adverse reaction to previous tms or mri exposure * active substance use disorder in the past 6 months, excluding tobacco use disorder, as diagnosed by study physicians

Keywords: neuromodulation chemo-brain
scleroderma arfi imaging of the skin

Conditions: Scleroderma

Summary: scleroderma and other rheumatologic conditions can affect the skin. scleroderma in particular involves skin thickening and hardening. currently, looking at the degree that the skin is affected by scleroderma is measured based on a combination of a physical exam and a skin biopsy. the researchers propose to measure skin hardness using ultrasound imaging of elasticity. they will use a technique using acoustic radiation force impulse/shear wave velocity imaging , known as arfi/svi). the investigators hypothesize that arfi/svi may be able to distinguish between normal skin and skin affected by scleroderma.. this tool may also help to quantify the amount of fibrosis in the skin. this type of radiologic biomarker could be used to help confirm the diagnosis of scleroderma.

scleroderma as well as numerous other rheumatologic conditions can affect the skin. scleroderma in particular causes skin thickening and hardening. currently, evaluation of degree to which skin is affected by scleroderma is measured by a combination of a physical exam and skin biopsy results. the investigators propose to measure skin hardness using ultrasound elasticity imaging, in the form of acoustic radiation force impulse/shear wave velocity imaging (arfi/svi). the investigators hypothesize that arfi/svi may be able to distinguish normal skin from skin affected by scleroderma (and other rheumatologic conditions). and, this ultrasound technique might measure the amount of fibrosis in the dermis (skin). such a radiologic biomarker could be used to help confirm the diagnosis of scleroderma. in addition, it may be usable for following patients over time and measuring their response to therapy and progression of disease.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. rheumatologic disease of the skin including: limited scleroderma, diffuse scleroderma, or eosinophilic fascitis (schulman's syndrome) exclusion criteria: 1. none
solve together: a data collection platform for the collection of patient and control health information to support future research that will accelerate understanding of the causes of and possible treatments for me/cfs and other chronic diseases, including post-viral illnesses

Conditions: Post-Acute COVID-19 Syndrome; ME/CFS

Summary: solve together is a platform designed to collect clinical data about post-infectious diseases, including me/cfs and long covid. this data is made available to researchers and will be used to identify participants eligible for clinical studies. the platform also empowers patients to make reports for their doctors, connect medical records and/or a health-tracking wearable device, and identify their unique symptoms and health patterns.

solve together description coming soon. the combination of data and integration with wearable technologies and ehrs will : (1) improve our understanding of the natural history, epidemiology, pathogenesis, resilience/susceptibility factors, disease subsets, and treatment of me/cfs and long-covid using a standardized set of demographic and longitudinal data; (2) build an infrastructure and resource to support a range of clinical research participation opportunities for these patients; (3) increase opportunities for collaboration between patients, providers, researchers, and industry. anyone 18 years of age and older is invited to sign up. after creating a profile and completing an informed consent via an online portal, participants fill out a series of surveys, including medical history, co-occurring conditions, symptoms, quality of life, and functional status. participants receive email or text reminders to complete additional surveys to provide researchers with information about eligibility for clinical research. solve together includes a mobile tracking app co-created with patients that allow participants to monitor symptoms and triggers and set pacing notifications. data are stored in a secure, encrypted database. data are aggregated and anonymized before being made available on a secure platform for research. this project is supported by solve me/cfs initiative. you can learn more and sign up starting september 12, 2023, at https://solvecfs.org/research/solve-together/

Eligibility criteria:
inclusion criteria: * patients with me/cfs, * patients with long covid * those without me/cfs or long covid

Keywords: long covid myalgic encephalomyelitis chronic fatigue syndrome
feasibility of motor-cognitive home training for parkinson's disease using ehealth technology

Conditions: Idiopathic Parkinson Disease; Telerehabilitation; Physical Therapy

Summary: the purpose of this study is to test the feasibility of a novel motor-cognitive home training intervention using ehealth technology among people with parkinson's disease


Eligibility criteria:
inclusion criteria: * neurologist diagnosed idiopathic pd at least 6 months previous to inclusion. * hoehn \& yahr stages i-iii * stable in anti-parkinson medications three months prior to inclusion. * the ability to walk walk independently indoors without a walking aid. * the ability to walk continually with/without a walking aid for at least 5 minutes. exclusion criteria: * cognitive impairment affecting the ability to understand or follow verbal or written instructions (montreal cognitive assessment ≤ 21 points). * impaired vision and/or impaired communication which hinders participation. * major problems with freezing and/or two or more falls in the month previous to inclusion. * other existing neurological/ orthopedic or cardiovascular disease which impedes the performance of unsupervised exercise in the home. * no internet connection in the home.

Keywords: motor-cognitive training home training
bendamustin hydrochloride in patients with soft tissue sarcoma (sts)

Conditions: Sarcoma, Soft Tissue

Summary: the aims of this trial are to evaluate the efficacy of bendamustin in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd chemotherapy and to assess the treatment of toxicity.


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic or non-resectable soft tissue sarcoma * evidence of progression or relapse after an anthracycline-based and/ or ifosfamide-based chemotherapy * at least 1 bidimensionally measurable tumor lesion according to recist criteria * no previous radiation therapy on the only measurable lesion * willingness to receive regular follow-up * life expectancy more than 3 months * ecog status \>= 2 * patients aged 18 years and beyond * leucocytes \> 2500/µl, thrombocytes \> 75000/µl) * serum creatine \ 60/ml * written patient informed consent * ability to give informed consent exclusion criteria: * previous or concurrent radiation of the index lesion (radiation of single lesion is allowed if not the index lesion) * insufficient liver function (bilirubin \> 1.5 the upper limit of normal, prolongation of pt and aptt \> 1.5 the upper limit of normal; asat and alat \> 3 the upper limit of normal (patients with liver metastases asat and alat \> 5 the upper limit of normal) * active infection * prior therapy with bendamustin hydrochloride * prior malignancies (other than adequately treated carcinoma in situ (cis) of the cervix, bladder urothelium, basal cell carcinoma or adenoma of the colon including ptis,ptin), unless treated with curative intent and without evidence of disease \> 5 years * symptomatic cardio- and/or cerebrovascular disease (nyha-scale iii°) * interval since last chemotherapy \< 4 weeks * evidence of cns-metastases * evidence of pregnancy or lactation * woman of child-bearing potential without reliable methods of birth control
implanted loop recorder post atrial fibrillation ablation

Conditions: Atrial Fibrillation

Summary: this is a pilot study to determine if implanted loop recorders can more effectively monitor atrial fibrillation recurrence after atrial fibrillation ablation.

atrial fibrillation (af)is the most common arrhythmia and causes significant morbidity and mortality. treatment for af consists of medical therapy and ablation therapy. medical therapies can help approximately 50% of patients, the rest must resort to ablation procedures. ablation procedures aim to isolate the pulmonary vein from the atrial tissue electrically and can be performed either endocardially through catheters inserted through the femoral veins or epicardially through a minimal lateral thoracotomy. both procedures are accepted as standard of care. recurrent af after ablation therapy can be common and occurs in 50% of patients and could be in a form of short periods of af or persistent af with less or minimal symptoms. this is of significant clinical relevance as most of these af episodes are not recognized and can lead to thromboembolic events such as stroke. however, techniques of surveillance of af post ablation have been suboptimal. physicians could use holter monitoring but this is limited to a short period of 24 - 48 hours. event recorders which are external can be used but patients need to experience symptoms associated with the af episodes in order to record the episodes. better af monitoring techniques especially after af ablation are necessary so that recognition of af recurrence in these patient could be possible and timely anticoagulation therapy initiated may prevent strokes. this pilot study involves implanting a loop recorder just under the skin to record cardiac rhythms 24 hours per day without any interaction by the patient. these devices are currently approved by the fda for monitoring of syncope and will be implanted during the patients af ablation surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing surgical atrial fibrillation ablation * patients must be 18 years or older exclusion criteria: * patients unwilling to comply with the follow up schedule * pregnant or breastfeeding patients * patients currently participating in another study

Keywords: atrial fibrillation surgical ablation implanted loop recorder atrial fibrillation ablation
resistance to lamivudine in hbv egyptian patients

Conditions: Chronic Hepatitis B Virus Treatment

Summary: on treatment parameters for lamivudine resistance in hbv treated egyptian patients

primarily: to study the correlations between the following parameters in adult egyptian patients with chronic viral hepatitis b before treatment: * alt. * hbeag. * hbv-dna by quantitative pcr. * biopsy (if possible). secondarily: after receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.

Eligibility criteria:
inclusion criteria: * adult patients \>18 years old * egyptian nationality * positive serology for hbsag for more than 6 months * positive hbv viremia (above 2000iu/ml). * lamivudine monotherapy exclusion criteria: * anti-hbcigm seropositivity * positive serology for hcv * positive serology for hdv * patients complicated with hcc

Keywords: hepatitis b virus lamivudine resistance to treatment
a comparison of lamivudine and zidovudine, used alone and together, in hiv-infected patients who have not used zidovudine in the past

Conditions: HIV Infections

Summary: to evaluate the safety and efficacy of high-dose lamivudine (3tc) alone versus zidovudine (azt) alone versus 3tc at high and low doses in combination with azt in hiv-1 infected patients. per 02/27/95 amendment: to evaluate the efficacy and safety of both blinded and open-label combination therapy.

patients are randomized to one of four treatment arms: 3tc alone, azt alone, low-dose 3tc plus azt, or high-dose 3tc plus azt. patients receive treatment for 32 weeks, with possible extension to 52 weeks. per 02/27/95 amendment: patients may continue therapy on azt and low-dose 3tc on an open-label basis. open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.

Eligibility criteria:
inclusion criteria patients must have: * hiv positivity. * cd4 count 200-500 cells/mm3. * azt naive status (\<= 4 weeks of prior azt). exclusion criteria patients with the following prior condition are excluded: history of intolerance to azt. prior medication: excluded: * more than 4 weeks of prior azt. * any prior antiretroviral treatment other than azt.

Keywords: drug therapy, combination acquired immunodeficiency syndrome aids-related complex antiviral agents zidovudine
pd of vay736 in patients with primary sjögren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: this study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of vay7346 monoclonal antibody in pss patients

patients were enrolled in 2 sequential cohorts: cohort 1: 6 patients received 3 mg/kg or placebo (2:1 ratio) cohort 2: 21 patients received 10 mg/kg, 3 mg/kg or placebo (6:1:3 ratio) at week 24 the blind was broken to assess continuation in the trial: * if a patient received vay736 and their b cell recovery was demonstrated at week 24, then patients completed the trial. * if a patient received vay736 and their b cell recovery was not demonstrated at week 24, then patients were followed up until b cell recovery was demonstrated * if a patient received placebo, they were offered the option of receiving open-label vay736 (10 mg/kg) in a separate treatment arm.

Eligibility criteria:
inclusion criteria: * fulfilled revised european us consensus criteria for pss * essdai value ≥ 6 * elevated serum titers at screening of ana (≥ 1:160) * seropositive at screening for anti-ssa and/or anti-ssb antibodies * stimulated whole salivary flow rate at screening of \> 0 ml/min exclusion criteria: - prior or previous use of (specific dosages and intervals prior to study start may apply): b-cell depleting therapy (e.g., rituximab), prednisone, anti-baff mab, ctla4-fc ig (abatacept), anti-tnf-α mab, cyclophosphamide, azathioprine and medications known to cause dry mouth. hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to randomization is allowed * active or recent history of clinically significant infection * vaccination within 2 month prior to study * history of primary or secondary immunodeficiency

Keywords: primary sjögren's syndrome, pharmacodynamics